Last reviewed · How we verify
MCT/LCT (1:1)
MCT/LCT (1:1) is a lipid emulsion that provides a balanced mixture of medium-chain triglycerides and long-chain triglycerides for parenteral nutrition.
MCT/LCT (1:1) is a lipid emulsion that provides a balanced mixture of medium-chain triglycerides and long-chain triglycerides for parenteral nutrition. Used for Parenteral nutrition in patients unable to receive adequate enteral nutrition, Source of calories and essential fatty acids in clinical nutrition support.
At a glance
| Generic name | MCT/LCT (1:1) |
|---|---|
| Also known as | LIPOFUNDINA |
| Sponsor | B. Braun Medical SA |
| Drug class | Lipid emulsion for parenteral nutrition |
| Modality | Small molecule |
| Therapeutic area | Nutrition support |
| Phase | FDA-approved |
Mechanism of action
This intravenous lipid emulsion combines MCTs (medium-chain triglycerides), which are rapidly metabolized and provide quick energy, with LCTs (long-chain triglycerides), which provide essential fatty acids and longer-term energy substrate. The 1:1 ratio is designed to optimize both rapid energy availability and essential fatty acid provision while potentially reducing metabolic complications associated with pure LCT or pure MCT formulations.
Approved indications
- Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition
- Provision of essential fatty acids and energy in critically ill or post-operative patients
Common side effects
- Hypertriglyceridemia
- Infusion site reactions
- Hepatic steatosis (with prolonged use)
- Allergic reactions
Key clinical trials
- Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study (PHASE2, PHASE3)
- Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants (PHASE2)
- Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery (NA)
- Effects of Fat Emulsions on PNALD and Oxidative Stress in Premature Infants (PHASE4)
- Different Lipid Emulsions in Acute Lung Injury Patients (PHASE4)
- ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients (PHASE4)
- Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants (PHASE4)
- Efficacy and Safety of a Fish Oil Containing Lipid Emulsion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCT/LCT (1:1) CI brief — competitive landscape report
- MCT/LCT (1:1) updates RSS · CI watch RSS
- B. Braun Medical SA portfolio CI